Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences Track

Clinical impact of F-18 Flutemetamol (FMM) PET to assess cerebral Aß pathology in patients with various cognitive disorders.

Naoya Hattori, Shogo Ono, NIKI UDO, Shin Yamamoto, Mikako Ogawa and Hiroki Sugie
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 480;
Naoya Hattori
3Diagnostic Radiology and Nuclear Medicine LSI Sapporo Clinic Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shogo Ono
3Diagnostic Radiology and Nuclear Medicine LSI Sapporo Clinic Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKI UDO
1Hokkaido University Graduate School of Medicine Spporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shin Yamamoto
4Tenshi Hospital Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikako Ogawa
2Hokkaido University Graduate School of Pharmaceutical Sciences Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroki Sugie
3Diagnostic Radiology and Nuclear Medicine LSI Sapporo Clinic Sapporo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

480

Objectives: Cerebral ß-amyloid (Aß) deposition significantly influences the clinical course not only in patients with suspected Alzheimer’s disease but also in other cognitive disorders. Therefore, accurate assessment of cerebral Aß pathology is necessary , which became possible with recently introduced fluorine-18 positron tracers. The purpose of this study was to investigate the clinical impact of F-18 Flutemetamol (FMM) PET to assess cerebral Aß pathology in patients with various cognitive disorders.

Methods: A total of 39 patients (18M, 21F, 73±13 years old) with various cognitive disorders of unestablished diagnoses (diagnostic confidence level less than 90%) underwent FMM PET to investigate cerebral beta-amyloid depositions. First, participating physicians were blinded to the results of FMM PET and discussed a summary of standard neuropsychological work-up (including conventional medical imaging) of each case to predict cerebral Aß pathology and to achieve a preliminary diagnosis. Second, the preliminary result was compared with the result of FMM PET to investigate its clinical impact. Clinical impact was considered positive when the result of FMM PET required revision of the preliminary neurological diagnosis.

Results: There were 21 patients with dementia (MMSE ≤ 24) and the remaining18 were patients with mild cognitive impairment (MCI). The conventional assessments predicted positive for Aß pathology in 12/21 in dementia, and 6/18 in MCI, while FMM-PET was positive for 4 and 12 patients, respectively. Clinical impact of FMM-PET was greater in MCI (8/18 = 44%) than in dementia (6/21 = 29%). The conventional assessments tended to over-diagnose Aß pathology particularly in MCI patients (Tables).

Conclusions: FMM-PET influenced neurological diagnosis in 36% (14/39) of patients with cognitive disorders. The impact was particularly higher in MCI patients, which may warrant the use of this technique for an accurate early diagnosis.

View this table:
  • View inline
  • View popup

MCI

View this table:
  • View inline
  • View popup

Dementia

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical impact of F-18 Flutemetamol (FMM) PET to assess cerebral Aß pathology in patients with various cognitive disorders.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Clinical impact of F-18 Flutemetamol (FMM) PET to assess cerebral Aß pathology in patients with various cognitive disorders.
Naoya Hattori, Shogo Ono, NIKI UDO, Shin Yamamoto, Mikako Ogawa, Hiroki Sugie
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 480;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Clinical impact of F-18 Flutemetamol (FMM) PET to assess cerebral Aß pathology in patients with various cognitive disorders.
Naoya Hattori, Shogo Ono, NIKI UDO, Shin Yamamoto, Mikako Ogawa, Hiroki Sugie
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 480;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences Track

  • Impact of cognitive reserve in frontotemporal dementia illustrated by FDG-PET.
  • Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with 18F-FEOBV
  • Kinetic evaluation of [18F]MOZAT PET imaging in humans.
Show more Neurosciences Track

Advancing Amyloid Imaging

  • Role of partial volume correction in paired studies of C-11 PiB vs F-18 florbetapir: implications for centiloid?
  • Stratifying the mortality risk of patients with cognitive impairment using PIB and FDG PET.
  • Correlation of Amyloid PET in Centiloid units with neuropathological findings in Alzheimer’s disease
Show more Advancing Amyloid Imaging

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire